News stories about Zoetis (NYSE:ZTS) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zoetis earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.4768988193003 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- Zoetis Inc (ZTS) Stake Lessened by Spark Investment Management LLC (americanbankingnews.com)
- Jefferies Group Analysts Give Zoetis (ZTS) a $97.00 Price Target (americanbankingnews.com)
- The Zacks Analyst Blog Highlights: Texas Instruments, Statoil, Comcast, Zoetis and HP (finance.yahoo.com)
- Zoetis Inc (ZTS) Shares Sold by Carnegie Capital Asset Management LLC (americanbankingnews.com)
- Low Wild stock to watch: Zoetis Inc. (ZTS) – Wallstreet Investorplace (wallstreetinvestorplace.com)
Zoetis (NYSE:ZTS) traded down $1.63 during mid-day trading on Tuesday, hitting $81.67. The stock had a trading volume of 2,240,856 shares, compared to its average volume of 3,230,000. The company has a quick ratio of 2.55, a current ratio of 3.85 and a debt-to-equity ratio of 2.77. The firm has a market capitalization of $39,800.00, a PE ratio of 37.46, a P/E/G ratio of 1.86 and a beta of 1.07. Zoetis has a 52 week low of $52.25 and a 52 week high of $83.46.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, April 20th will be given a dividend of $0.126 per share. The ex-dividend date is Thursday, April 19th. This represents a $0.50 annualized dividend and a dividend yield of 0.62%. Zoetis’s dividend payout ratio is currently 22.94%.
A number of equities research analysts recently commented on the company. Jefferies Group set a $97.00 price objective on Zoetis and gave the company a “buy” rating in a report on Monday. BMO Capital Markets set a $78.00 price objective on Zoetis and gave the company a “hold” rating in a report on Thursday, February 15th. Deutsche Bank upped their price objective on Zoetis from $76.00 to $78.00 and gave the company a “hold” rating in a report on Friday, February 16th. Bank of America upped their price objective on Zoetis from $80.00 to $87.00 and gave the company a “buy” rating in a report on Friday, February 16th. Finally, Piper Jaffray Companies set a $88.00 price objective on Zoetis and gave the company a “buy” rating in a report on Friday, February 16th. One analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the company. Zoetis currently has a consensus rating of “Buy” and a consensus target price of $80.28.
In other news, insider Heidi C. Chen sold 37,453 shares of the company’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $81.02, for a total transaction of $3,034,442.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Roman Trawicki sold 23,885 shares of the company’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $82.00, for a total value of $1,958,570.00. The disclosure for this sale can be found here. Insiders have sold 97,001 shares of company stock valued at $7,882,428 over the last ninety days. 0.31% of the stock is owned by insiders.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.